Physician profile
Elizabeth Jane Romano
NPI 1487321345
$4,040.06
in general payments reported to CMS, 2019-2025
50 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $90.46 · 2023: $782 · 2024: $1,561 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.63 |
| Education | $247.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $458.12 | 2022-2025 | Imfinzi, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $397.17 | 2023-2025 | |
| Janssen Biotech, INC. | $221.39 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Abbvie INC. | $217.92 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $200.97 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $189.56 | 2025 | Enhertu, Datroway, Vanflyta |
| Alexion Pharmaceuticals, INC. | $172.84 | 2024-2025 | Soliris, Ultomiris |
| Genzyme Corporation | $147.11 | 2022-2025 | |
| Amgen INC. | $145.05 | 2023-2024 | Lumakras |
| Beigene USA, INC. | $122.00 | 2023-2024 | Brukinsa |
| Stemline Therapeutics INC. | $121.18 | 2023 | Orserdu |
| Pfizer INC. | $111.81 | 2023-2024 | |
| Seagen INC. | $111.05 | 2023 | Tukysa |
| Tersera Therapeutics LLC | $99.82 | 2024-2025 | Zoladex, Xermelo |
| Eisai INC. | $97.65 | 2024-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Romano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.